If you have head and neck cancer that has returned or spread and are 18 years or older, you may qualify for a research study
The research study will test an investigational drug* called ADU-S100 that will be given with a drug called KEYTRUDA®. KEYTRUDA® is an immunotherapy that has already been approved by the FDA to treat your type of cancer. ADU-S100 is believed to work by stimulating your immune system to fight cancer. The purpose of this study is to find out if ADU-S100 works and is safe for use with KEYTRUDA®.
ADU-S100 will be injected directly into your tumor once a week for two weeks, followed by one week of rest during every three week cycle. KEYTRUDA® will be given as an infusion once every three weeks.
YOU MAY BE ELIGIBLE IF:
- You have head and neck cancer that has returned or spread.
- Your cancer cannot be removed by surgery.
- Your cancer cells have a high amount of PDL1, a protein that helps keep immune responses in check. Testing your tumor for PD-L1 will be provided at no cost to you.
- Other criteria apply.
If you are interested in this study and to find out more, please visit ClinicalTrials.gov (Identifier: NCT03937141) for your nearest site contact and location information.
* An investigational drug is a drug that has not yet been approved by the FDA. Efficacy and safety have not been established. There is no guarantee that it will become commercially available for the use(s) under investigation.
Version 1.0 | March 6, 2020